title: The effect of combined antenatal vitamin K and phenobarbital therapy on umbilical blood coagulation studies in infants less than 34 weeks' gestation.
abstract: OBJECTIVE
  To determine if antenatal vitamin K and phenobarbital therapy affect coagulation studies in umbilical blood at birth, and to provide 95% reference ranges for umbilical blood coagulation parameters in premature gestations.
  
  
  METHODS
  Patients at imminent risk for spontaneous or indicated premature delivery less than 34 weeks' gestation were randomized to receive either placebo or vitamin K and phenobarbital. Prothrombin time (PT), activated partial thromboplastin time (PTT), functional coagulation factors, and decarboxylated prothrombin assays were performed on umbilical blood specimens. Decarboxylated prothrombin, also known as "protein induced by vitamin K absence-factor II" or precursor prothrombin, is a sensitive marker for vitamin K deficiency. Standardized values of PT and PTT are reported in seconds and standardized values of factor assays in percentage of normal adult functional activity (mean +/- one standard deviation).
  
  
  RESULTS
  Newborns in the placebo and treatment groups had similar umbilical blood PT (12.6 +/- 1.2 versus 12.7 +/- 1.4 seconds), PTT (48.8 +/- 13.4 versus 49.6 +/- 13.8 seconds), and functional activity of factor II (40.3 +/- 12.5 versus 42.0 +/- 12.1%), factor VII (67.0 +/- 20.9 versus 66.8 +/- 18.9%), factor IX (27.4 +/- 12.8 versus 25.8 +/- 8.9%), and factor X (47.0 +/- 12.8 versus 49.2 +/- 11.6%). Newborns in the treatment group were about half as likely as those in the placebo group to have detectable decarboxylated prothrombin levels in umbilical blood at birth (gestational age-adjusted odds ratio 0.47, 95% confidence interval 0.22-1.01; P = .05).
  
  
  CONCLUSIONS
  Combined maternal therapy with vitamin K and phenobarbital before premature delivery does not affect umbilical blood PT, PTT, or functional activity of vitamin K-dependent coagulation factors II, VII, IX, and X. However, it is associated with the reduced presence of decarboxylated prothrombin in umbilical blood at birth. There is significant improvement in umbilical blood coagulation tests as gestational age advances from 24 to 34 weeks.
authors.affiliation: Department of Obstetrics and Gynecology, Saint Luke's Hospital of Kansas City, Missouri, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Thorp
authors.forename: D R
authors.initials: DR
authors.lastname: Caspers
authors.forename: G R
authors.initials: GR
authors.lastname: Cohen
authors.forename: M L
authors.initials: ML
authors.lastname: Zucker
authors.forename: B D
authors.initials: BD
authors.lastname: Strope
authors.forename: D R
authors.initials: DR
authors.lastname: McKenzie
mesh_terms: D000328:Adult; D000465:Algorithms; D001777:Blood Coagulation / Q000187:drug effects*; D004311:Double-Blind Method; D005312:Fetal Blood / Q000187:drug effects* / Q000502:physiology*; D005865:Gestational Age; D006490:Hemostatics / Q000494:pharmacology*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature / Q000097:blood*; D010314:Partial Thromboplastin Time; D010634:Phenobarbital / Q000494:pharmacology*; D011295:Prenatal Care; D011517:Prothrombin Time; D012016:Reference Values; D014812:Vitamin K / Q000494:pharmacology*
chemical_list: D006490:Hemostatics; D014812:Vitamin K; D010634:Phenobarbital